Skip to main content
Addgene

Activity-based directed evolution of a membrane editor in mammalian cells.

Tei R, Bagde SR, Fromme JC, Baskin JM
Nat Chem. 2023 May 22. doi: 10.1038/s41557-023-01214-0. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
188986pCDH-CRY2-mCh-superPLDx10A lentiviral plasmid encoding CRY2-mCh-superPLDx10 (an engineered PLD mutant with 10 times higher activity than the wild-type)
188988pCDH-CRY2-mCh-superPLDx30A lentiviral plasmid encoding CRY2-mCh-superPLDx30 (an engineered PLD mutant with 30 times higher activity than the wild-type)
188989pCDH-CIBN-CAAXA lentiviral plasmid encoding plasma membrane-tagged CIBN
188990pCDH-p18-CIBNA lentiviral plasmid encoding lysosome-tagged CIBN
188991pCDNA-CRY2-mCh-superPLDx10-P2A-CIBN-CAAXA plasmid for dual expression of CRY2-mCh-superPLDx10 (an engineered PLD mutant with 10 times higher activity than the wild-type) and plasma membrane-tagged CIBN
188992pCDNA-CRY2-mCh-superPLDx30-P2A-CIBN-CAAXA plasmid for dual expression of CRY2-mCh-superPLDx30 (an engineered PLD mutant with 30 times higher activity than the wild-type) and plasma membrane-tagged CIBN
188993pCDNA-CRY2-mCh-superPLDx50-P2A-CIBN-CAAXA plasmid for dual expression of CRY2-mCh-superPLDx50 (an engineered PLD mutant with 50 times higher activity than the wild-type) and plasma membrane-tagged CIBN
188994pCDNA-CRY2-mCh-superPLDx100-P2A-CIBN-CAAXA plasmid for dual expression of CRY2-mCh-superPLDx100 (an engineered PLD mutant with 100 times higher activity than the wild-type) and plasma membrane-tagged CIBN

Antibodies from Article